Market Cap 113.25M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.17
Profit Margin -219.61%
Debt to Equity Ratio -0.12
Volume 392,900
Avg Vol 676,638
Day's Range N/A - N/A
Shares Out 34.01M
Stochastic %K 92%
Beta 1.62
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
2_logs_higher
2_logs_higher Mar. 3 at 11:38 PM
$AGEN congrats Dr Benny
1 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 11:25 PM
$SPY Please go to church. Stay close to God . This world is in spiritual warfare $AGEN
0 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 10:27 PM
$AGEN $SPY $HOOD we are going to tax you rich dk sckers out of business
1 · Reply
JohnG8
JohnG8 Mar. 3 at 7:52 PM
$AGEN I keep seeing these posts saying Garo do this and Garo do that. Those posts are pointless. Garo has some sort of personality defect that prevents him from doing the obviously correct thing. I don’t know what it is. It could stem from some sort of inferiority complex where he has to show the world he’s smarter than everybody else, and So has to find another path to FDA approval, rather than the usual phase 1–3. I truly don’t know. End result is that he is a crackpot, and we are stuck with him. All we can hope for is that he retires. 
2 · Reply
Biotechguy21
Biotechguy21 Mar. 3 at 4:45 PM
$AGEN zero chance. No one wants to buy a pos turd 💩💩💩💩💩
0 · Reply
neversurrender2024
neversurrender2024 Mar. 3 at 4:41 PM
$AGEN canada , france , garo couldnt have picked worst places for phase 3....canadas maid program killed 100k and its taking off...both countries turning toward socialism fast...
0 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 3:33 PM
$SPY $AGEN yayyyy my love for cats is immeasurable in scale and length . They will fill my heart with love forever
0 · Reply
neversurrender2024
neversurrender2024 Mar. 3 at 2:56 PM
$AGEN one week the earnings are out.... cant hide the mismanagement, garo will pitch more hopium...
0 · Reply
Stefman9
Stefman9 Mar. 3 at 1:44 PM
$AGEN Lets go Garo, make a deal with a big pharma, you have wasted years. It's time to make a deal with MRK, GILD, etc.. Garo just retire and let Bot/Bal move quickly to help patients. Your snail pace moving forward is severely flawed and lacking needed funding.
3 · Reply
Biotechguy21
Biotechguy21 Mar. 3 at 12:32 PM
$AGEN are you ready for the rug pull from this pos? it’s coming and highly predictable 😂😂🤡🤡💩💩
1 · Reply
Latest News on AGEN
Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 6 weeks ago

Agenus to Host First 2026 Stakeholder Webcast


Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Dec 4, 2025, 1:43 AM EST - 3 months ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 9 months ago

Agenus Announces Virtual Annual Shareholders Meeting


Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 9 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang


Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 10 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide


Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 10 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript


Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 10 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates


Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 1 year ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript


2_logs_higher
2_logs_higher Mar. 3 at 11:38 PM
$AGEN congrats Dr Benny
1 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 11:25 PM
$SPY Please go to church. Stay close to God . This world is in spiritual warfare $AGEN
0 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 10:27 PM
$AGEN $SPY $HOOD we are going to tax you rich dk sckers out of business
1 · Reply
JohnG8
JohnG8 Mar. 3 at 7:52 PM
$AGEN I keep seeing these posts saying Garo do this and Garo do that. Those posts are pointless. Garo has some sort of personality defect that prevents him from doing the obviously correct thing. I don’t know what it is. It could stem from some sort of inferiority complex where he has to show the world he’s smarter than everybody else, and So has to find another path to FDA approval, rather than the usual phase 1–3. I truly don’t know. End result is that he is a crackpot, and we are stuck with him. All we can hope for is that he retires. 
2 · Reply
Biotechguy21
Biotechguy21 Mar. 3 at 4:45 PM
$AGEN zero chance. No one wants to buy a pos turd 💩💩💩💩💩
0 · Reply
neversurrender2024
neversurrender2024 Mar. 3 at 4:41 PM
$AGEN canada , france , garo couldnt have picked worst places for phase 3....canadas maid program killed 100k and its taking off...both countries turning toward socialism fast...
0 · Reply
B4byB4n4n4Bear
B4byB4n4n4Bear Mar. 3 at 3:33 PM
$SPY $AGEN yayyyy my love for cats is immeasurable in scale and length . They will fill my heart with love forever
0 · Reply
neversurrender2024
neversurrender2024 Mar. 3 at 2:56 PM
$AGEN one week the earnings are out.... cant hide the mismanagement, garo will pitch more hopium...
0 · Reply
Stefman9
Stefman9 Mar. 3 at 1:44 PM
$AGEN Lets go Garo, make a deal with a big pharma, you have wasted years. It's time to make a deal with MRK, GILD, etc.. Garo just retire and let Bot/Bal move quickly to help patients. Your snail pace moving forward is severely flawed and lacking needed funding.
3 · Reply
Biotechguy21
Biotechguy21 Mar. 3 at 12:32 PM
$AGEN are you ready for the rug pull from this pos? it’s coming and highly predictable 😂😂🤡🤡💩💩
1 · Reply
MilaGoldframe01
MilaGoldframe01 Mar. 3 at 12:12 PM
Sold $NTLA, $AGEN yesterday to be liquid for the Index mess today $DAX L 23730 big pos. glta in these stormy times. Sad it had to come to this...happy for the people of Iran though.
0 · Reply
2_logs_higher
2_logs_higher Mar. 3 at 2:50 AM
$AGEN Have to say - I'm shocked, not a single comment on Bianca Harvey with Dr DeVito, Duke, full remission of Stage 4 CRC using BOT + BAL. https://today.duke.edu/sites/default/files/2026-02/202511043_harvey304b.jpg The tumor in her colon hurt so much Bianca Harvey felt like she was being stabbed in the stomach. A 34-year-old teacher, she went to the hospital after a colleague found her literally doubled over in pain in her sixth-grade classroom. The Fayetteville native, a former college track athlete, bodybuilder and kickboxer, had stage IV cancer. But Duke oncologist Nicholas DeVito had a plan. Bianca began a clinical trial with chemotherapy – which she received at Duke every other Thursday for 18 months. When that was no longer effective, she shifted to immunotherapy. She now has dozens of updates illuminating her cancer experience. “You can keep it to yourself, or you can speak about it to the world and maybe help someone else,” she said. Her story keeps getting better: Her most recent scans came back completely clear of cancer.
3 · Reply
joechuck71
joechuck71 Mar. 3 at 1:43 AM
$AGEN 🧬 Clinical strength: clearly improved The newest BOT/BAL data show durable survival across multiple refractory solid tumors, with roughly 39–40% of patients alive at two years in heavily pretreated populations. That’s unusually strong for late‑line, immunotherapy‑resistant cancers. Key points from the data: • Activity across multiple tumor types, including historically cold tumors • 17% ORR across expansion cohorts • Median OS ~17–21 months depending on subgroup • No treatment‑related deaths, manageable immune toxicity • Signals of tumor‑agnostic potential Scientifically, this is the strongest position Agenus has ever been in. Big pharma cares about OS plateaus, and BOT/BAL is showing exactly that.
0 · Reply
joechuck71
joechuck71 Mar. 3 at 1:40 AM
$AGEN 📊 Why the “132 patients” threshold matters France typically wants ~132 treated patients to generate a robust RWE package for: • Safety characterization • Early effectiveness signals • Health‑economic modeling • Transition to AAP (early access with negotiated pricing) Reaching this threshold is a major inflection point because it can lead to: • Higher-volume access • More stable pricing • Influence on other EU countries’ decisions Given the expanded indications, France is now positioned to reach 132 faster.
1 · Reply
AAAGenBot
AAAGenBot Mar. 2 at 11:08 PM
$AGEN Update to the phase 3 trial NCT06346197 - Esogastric Adenocarcinomas - now enrolling at 3 sites. France only. Need 132 patients.
1 · Reply
Biotechguy21
Biotechguy21 Mar. 2 at 8:13 PM
$AGEN what dilution? 😂😂😂😂
0 · Reply
Overcrumb
Overcrumb Mar. 2 at 6:45 PM
$AGEN nothing happening here. Seems like no interest. Agenus needs to get something done soon before this war escalates to a point where….
3 · Reply
neversurrender2024
neversurrender2024 Mar. 2 at 6:32 PM
$AGEN cant wait to see those dilution numbers....
0 · Reply
pedmac2000
pedmac2000 Mar. 2 at 6:05 PM
$AGEN since both ibrx and agenus have similar drugs why is agenus lagging so badly- PART 1 Good question — and you’re actually noticing something very real in biotech markets. On the surface ImmunityBio, Inc. (IBRX) and Agenus Inc. (AGEN) look similar: both are immunotherapy companies, both work with checkpoint-related biology, and both talk about activating T-cells to fight cancer. But the market is not pricing “science similarity.” It is pricing probability of near-term revenue and survival risk. Here’s why AGEN is lagging badly: 1) One has an FDA-approved commercial drug — the other still doesn’t This is the single biggest reason. IBRX IBRX now has an approved therapy (N-803 platform in bladder cancer). That instantly changes a biotech from a research story → to a revenue company. Wall Street re-rates a company the moment it crosses this line: clinical hope → reimbursable medicine Because now: hospitals can bill Medicare insurers reimburse sales projections exist pharma
2 · Reply
2_logs_higher
2_logs_higher Mar. 2 at 4:09 PM
$AGEN and others involved in bot+bal
0 · Reply
neversurrender2024
neversurrender2024 Mar. 2 at 4:00 PM
$AGEN good morning stuck holders... a week from tomorrow the bottom falls out, earnings,atm usage numbers and still no phase 3, pushed back until 3/31 and watch garo miss that dead line as well...
0 · Reply
2_logs_higher
2_logs_higher Mar. 2 at 3:41 PM
$AGEN BOT + BAL in the news
3 · Reply